59 related articles for article (PubMed ID: 14666606)
1. Prognostic value of blood-based protein biomarkers in non-small cell lung cancer: A critical review and 2008-2022 update.
Trulson I; Holdenrieder S
Tumour Biol; 2024; 46(s1):S111-S161. PubMed ID: 37927288
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of tumor markers ProGRP, NSE and CYFRA 21-1 in patients with small cell lung cancer and chemotherapy-induced remission.
Muley T; Herth FJ; Heussel CP; Kriegsmann M; Thomas M; Meister M; Schneider MA; Wehnl B; Mang A; Holdenrieder S
Tumour Biol; 2024; 46(s1):S219-S232. PubMed ID: 37840518
[TBL] [Abstract][Full Text] [Related]
3. Relevance of tumor markers for prognosis and predicting therapy response in non-small cell lung cancer patients: A CEPAC-TDM biomarker substudy.
Geiger K; Joerger M; Roessler M; Hettwer K; Ritter C; Simon K; Uhlig S; Holdenrieder S
Tumour Biol; 2024; 46(s1):S191-S206. PubMed ID: 38363625
[TBL] [Abstract][Full Text] [Related]
4. Role of CYFRA 21-1 and CEA as prognostic and predictive markers in locally advanced and metastatic gastric carcinoma.
Gopal V; Nisha Y; Ganesan P; Kayal S; Bobby Z; Adithan S; Penumadu P; Ramakrishnalay VP; Bandlamudi BP; Bahttacharjee A; Dahagama S; Dubashi B
J Cancer Res Ther; 2024 Jan; ():. PubMed ID: 38261458
[TBL] [Abstract][Full Text] [Related]
5. Pre-analytical stability of the CEA, CYFRA 21.1, NSE, CA125 and HE4 tumor markers.
Canki E; Schuurbiers MM; Linders TC; Korse CM; van den Heuvel MM; van Herwaarden AE; van Rossum HH
Tumour Biol; 2024; 46(s1):S15-S25. PubMed ID: 37302060
[TBL] [Abstract][Full Text] [Related]
6. CYFRA 21-1, CA 125 and CEA provide additional prognostic value in NSCLC patients with stable disease at first CT scan.
Muley T; Schneider MA; Meister M; Thomas M; Heußel CP; Kriegsmann M; Holdenrieder S; Wehnl B; Rolny V; Mang A; Gerber R; Herth F
Tumour Biol; 2024; 46(s1):S163-S175. PubMed ID: 37840516
[TBL] [Abstract][Full Text] [Related]
7. Trajectory patterns and cumulative burden of CEA during follow-up with non-small cell lung cancer outcomes: A retrospective longitudinal cohort study.
Li C; Liu L; You R; Li Y; Pu H; Lei M; Fan B; Lv J; Liu M; Yan G; Li Z; You D; Zhang T
Br J Cancer; 2024 Apr; ():. PubMed ID: 38594371
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of preoperative exercise tolerance in patients with early-stage lung cancer.
Fukui M; Matsunaga T; Hattori A; Takamochi K; Tomita H; Nojiri S; Suzuki K
J Thorac Cardiovasc Surg; 2024 Jan; ():. PubMed ID: 38218531
[TBL] [Abstract][Full Text] [Related]
9. Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role.
Wieskopf B; Demangeat C; Purohit A; Stenger R; Gries P; Kreisman H; Quoix E
Chest; 1995 Jul; 108(1):163-9. PubMed ID: 7541742
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic value of CEA and CYFRA 21-1 tumor markers in primary lung cancer.
Okamura K; Takayama K; Izumi M; Harada T; Furuyama K; Nakanishi Y
Lung Cancer; 2013 Apr; 80(1):45-9. PubMed ID: 23352032
[TBL] [Abstract][Full Text] [Related]
11. The clinical value of Cyfra 21-1 estimation for lung cancer patients.
Szturmowicz M; Sakowicz A; Rudzinski P; Zych J; Wiatr E; Zaleska J; Rowinska-Zakrzewska E
Int J Biol Markers; 1996; 11(3):172-7. PubMed ID: 8915713
[TBL] [Abstract][Full Text] [Related]
12. A combination of radiomic features, clinic characteristics, and serum tumor biomarkers to predict the possibility of the micropapillary/solid component of lung adenocarcinoma.
Xing X; Li L; Sun M; Zhu X; Feng Y
Ther Adv Respir Dis; 2024; 18():17534666241249168. PubMed ID: 38757628
[TBL] [Abstract][Full Text] [Related]
13. Clinical Laboratory Results as Prognosis Marker in Advanced Stage Non-small Cell Lung Cancer (NSCLC) in Indonesia.
Hanafi AR; Jayusman AM; Sutandyo N; Kurniawati S; Setiawan L; Diandra A; Hidayat K
Cureus; 2022 Sep; 14(9):e29386. PubMed ID: 36304376
[TBL] [Abstract][Full Text] [Related]
14. CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors.
Dall'Olio FG; Abbati F; Facchinetti F; Massucci M; Melotti B; Squadrilli A; Buti S; Formica F; Tiseo M; Ardizzoni A
Ther Adv Med Oncol; 2020; 12():1758835920952994. PubMed ID: 33193825
[TBL] [Abstract][Full Text] [Related]
15. Systematic review of CYFRA 21-1 as a prognostic indicator and its predictive correlation with clinicopathological features in Non-small Cell Lung Cancer: A meta-analysis.
Yu Z; Zhang G; Yang M; Zhang S; Zhao B; Shen G; Chai Y
Oncotarget; 2017 Jan; 8(3):4043-4050. PubMed ID: 28008142
[TBL] [Abstract][Full Text] [Related]
16. Pathologic correlation of serum carcinoembryonic antigen and cytokeratin 19 fragment in resected nonsmall cell lung cancer.
Lee S; Lee CY; Kim DJ; Hong DJ; Lee JG; Chung KY
Korean J Thorac Cardiovasc Surg; 2013 Jun; 46(3):192-6. PubMed ID: 23772406
[TBL] [Abstract][Full Text] [Related]
17. CYFRA 21-1 as a prognostic and predictive marker in advanced non-small-cell lung cancer in a prospective trial: CALGB 150304.
Edelman MJ; Hodgson L; Rosenblatt PY; Christenson RH; Vokes EE; Wang X; Kratzke R
J Thorac Oncol; 2012 Apr; 7(4):649-54. PubMed ID: 22425913
[TBL] [Abstract][Full Text] [Related]
18. Biomarkers in lung cancer: from early detection to novel therapeutics and decision making.
Scott A; Salgia R
Biomark Med; 2008 Dec; 2(6):577-586. PubMed ID: 19802373
[TBL] [Abstract][Full Text] [Related]
19. Increased CYFRA 21-1 and CEA levels are negative predictors of outcome in p-stage I NSCLC.
Muley T; Dienemann H; Ebert W
Anticancer Res; 2003; 23(5b):4085-93. PubMed ID: 14666606
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
